News & Insights

Tarsus Pharmaceuticals announces its definitive agreement to acquire Alkeus Pharmaceuticals, a privately held retinal disease-focused biotechnology company developing gildeuretinol (ALK-001), an investigational once-daily oral therapy for Stargardt disease.

Osanni Bio announces its $190 million Series B financing.

Pachama, a climate technology pioneer, announces its acquisition by Carbon Direct.

Best Lawyers recognizes 38 Gunderson Dettmer attorneys across both the 2026 editions of The Best Lawyers in America list and Best Lawyers: Ones to Watch in America, continuing the legacy of celebrating exceptional legal professionals who have distinguished themselves through insight, expertise, and commitment to excellence

Gunderson Dettmer has elected 11 new partners, effective January 1, 2023. These elevations add to the firm’s Corporate and Securities, Executive Compensation, Fund Formation, and Licensing, Strategic Partnering and Commercial Transactions practices.